On, those willing to BLU-554 custom synthesis receive CYC tended to have higher perceived effectiveness (22.12 vs 17.44, P < 0.001) and lower perceived risk (10.92 vs 11.72, P = 0.05) of treatment. Willingness to receive CYC waswww.rheumatology.oxfordjournals.orgTreatment preferences in lupusTABLE 1 SLE patient sociodemographic and clinical characteristics by racial/ethnic groupCharacteristic Number of subjects, n Age, mean (S.D.), years More than HS graduate, n ( ) Income, n ( ) < 10 000 10 00130 000 30 00150 000 > 50 000 Employed, n ( ) With private medical insurance, n ( ) Married, n ( ) SLEDAI, mean (S.D.) SLICC Damage Index, mean (S.D.) AG-490MedChemExpress AG-490 Charlson Comorbidity, mean (S.D.) CES-D, mean (S.D.)aAfrican-American 120 41.58 (12.70) 77 (64.2) 40 32 23 24 46 42 37 3.32 2.02 2.34 19.48 (33.6) (26.9) (19.3) (20.2) (38.5) (35.0) (30.8) (3.39) (2.19) (1.43) (12.26)White 62 45.24 (11.94) 52 (83.9) 3 5 10 38 35 52 41 2.95 1.71 1.85 15.92 (5.4) (8.9) (17.9) (67.9) (56.5) (83.9) (66.1) (2.71) (2.56) (1.28) (12.32)P-valuea0.06 <0.01 <0.0.02 <0.001 <0.001 0.52 0.22 0.03 0.Significance level of the w2 (or Fisher's exact) statistic for categorical variables and two-tailed t-test (or Wilcoxon's rank sum test) for continuous variables. HS: high school.TABLE 2 SLE patient preferences and perceptions regarding aggressive treatmentAfrican-American Willing to receive CYC, n ( )b Familiarity, mean (S.D.) Perception of effectiveness, mean (S.D.) Perception of risk, mean (S.D.) Willing to participate in a clinical trial involving a new medication, n ( )caWhite 45 0.57 21.25 11.11 46 (84.9) (0.82) (4.27) (2.33) (80.7)P-valuea 0.02 0.10 0.44 0.95 0.63 0.36 20.67 11.14(67.0) (0.67) (4.37) (2.11) (68.7)Significance level of the w2 statistic for categorical variables and two-tailed t-test (or Wilcoxon's rank sum test) for continuous variables. bAmong patients who had never received CYC (n = 147, 94 African-American and 53 white). cAmong patients who had never participated in a clinical trial involving a new medication (n = 172, 115 African-American and 57 white).also significantly associated with a higher trust in physicians score (39.08 vs 35.79, P = 0.03), but not with physician PDM style score, locus of control or perceived discrimination in medicine. Married patients were more willing than single, divorced or widowed patients to participate in a clinical trial involving an experimental medication (80.8 vs 66.7 , P = 0.04). Willingness to participate in a clinical trial was also associated with having a lower internal locus of control score (24.75 vs 26.74, P = 0.03) and believing that having a rheumatologist of the same race (P = 0.02) and age (P = 0.05) are very unimportant. Those willing to participate in a clinical trial also had a significantly higher perceived physician PDM style mean score (72.20 vs 56.74, P < 0.001). Yet, clinical trial participation was unrelated to physicianpatient relationship duration, trust in physicians or perceived discrimination.of the odds of willingness to receive CYC: AfricanAmerican race [odds ratio (OR) 0.29, 95 CI 0.10, 0.80)], trust in physicians (OR 1.05, 95 CI 1.00, 1.12) and perceptions of effectiveness of CYC (OR 1.40, 95 CI 1.22, 1.61). Similarly, a separate logistic regression analysis demonstrated that the following were significant determinants of the odds of willingness to participate in a clinical trial: internal health locus of control (OR 0.93, 95 CI 0.86, 0.99), physician PDM style (OR 1.03, 95 CI 1.01, 1.04), lack of physician ra.On, those willing to receive CYC tended to have higher perceived effectiveness (22.12 vs 17.44, P < 0.001) and lower perceived risk (10.92 vs 11.72, P = 0.05) of treatment. Willingness to receive CYC waswww.rheumatology.oxfordjournals.orgTreatment preferences in lupusTABLE 1 SLE patient sociodemographic and clinical characteristics by racial/ethnic groupCharacteristic Number of subjects, n Age, mean (S.D.), years More than HS graduate, n ( ) Income, n ( ) < 10 000 10 00130 000 30 00150 000 > 50 000 Employed, n ( ) With private medical insurance, n ( ) Married, n ( ) SLEDAI, mean (S.D.) SLICC Damage Index, mean (S.D.) Charlson Comorbidity, mean (S.D.) CES-D, mean (S.D.)aAfrican-American 120 41.58 (12.70) 77 (64.2) 40 32 23 24 46 42 37 3.32 2.02 2.34 19.48 (33.6) (26.9) (19.3) (20.2) (38.5) (35.0) (30.8) (3.39) (2.19) (1.43) (12.26)White 62 45.24 (11.94) 52 (83.9) 3 5 10 38 35 52 41 2.95 1.71 1.85 15.92 (5.4) (8.9) (17.9) (67.9) (56.5) (83.9) (66.1) (2.71) (2.56) (1.28) (12.32)P-valuea0.06 <0.01 <0.0.02 <0.001 <0.001 0.52 0.22 0.03 0.Significance level of the w2 (or Fisher's exact) statistic for categorical variables and two-tailed t-test (or Wilcoxon's rank sum test) for continuous variables. HS: high school.TABLE 2 SLE patient preferences and perceptions regarding aggressive treatmentAfrican-American Willing to receive CYC, n ( )b Familiarity, mean (S.D.) Perception of effectiveness, mean (S.D.) Perception of risk, mean (S.D.) Willing to participate in a clinical trial involving a new medication, n ( )caWhite 45 0.57 21.25 11.11 46 (84.9) (0.82) (4.27) (2.33) (80.7)P-valuea 0.02 0.10 0.44 0.95 0.63 0.36 20.67 11.14(67.0) (0.67) (4.37) (2.11) (68.7)Significance level of the w2 statistic for categorical variables and two-tailed t-test (or Wilcoxon's rank sum test) for continuous variables. bAmong patients who had never received CYC (n = 147, 94 African-American and 53 white). cAmong patients who had never participated in a clinical trial involving a new medication (n = 172, 115 African-American and 57 white).also significantly associated with a higher trust in physicians score (39.08 vs 35.79, P = 0.03), but not with physician PDM style score, locus of control or perceived discrimination in medicine. Married patients were more willing than single, divorced or widowed patients to participate in a clinical trial involving an experimental medication (80.8 vs 66.7 , P = 0.04). Willingness to participate in a clinical trial was also associated with having a lower internal locus of control score (24.75 vs 26.74, P = 0.03) and believing that having a rheumatologist of the same race (P = 0.02) and age (P = 0.05) are very unimportant. Those willing to participate in a clinical trial also had a significantly higher perceived physician PDM style mean score (72.20 vs 56.74, P < 0.001). Yet, clinical trial participation was unrelated to physicianpatient relationship duration, trust in physicians or perceived discrimination.of the odds of willingness to receive CYC: AfricanAmerican race [odds ratio (OR) 0.29, 95 CI 0.10, 0.80)], trust in physicians (OR 1.05, 95 CI 1.00, 1.12) and perceptions of effectiveness of CYC (OR 1.40, 95 CI 1.22, 1.61). Similarly, a separate logistic regression analysis demonstrated that the following were significant determinants of the odds of willingness to participate in a clinical trial: internal health locus of control (OR 0.93, 95 CI 0.86, 0.99), physician PDM style (OR 1.03, 95 CI 1.01, 1.04), lack of physician ra.
